Brief: Pliant Therapeutics Provides Update On Beacon-IPF
03/03/2025 14:50
March 3 (Reuters) - Pliant Therapeutics Inc PLRX.O: PLIANT THERAPEUTICS PROVIDES UPDATE ON BEACON-IPF, A PHASE 2B/3 TRIAL IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS PLIANT THERAPEUTICS INC - DISCONTINUES BEACON-IPF PHASE 2B TRIAL PLIANT THERAPEUTICS INC - TRIAL DISCONTINUED DUE TO IPF-RELATED ADVERSE EVENTS PLIANT THERAPEUTICS INC - COMMITTED TO DEVELOPMENT OF OTHER CLINICAL ASSETS INCLUDING PLN-101095 IN ONCOLOGY PLIANT THERAPEUTICS INC: EARLY EVIDENCE OF EFFICACY ON FORCED VITAL CAPACITY (FVC) ENDPOINT WAS ALSO OBSERVED IN BEACON-IPF TRIAL Source text: ID:nGNX2pcbQM Further company coverage: PLRX.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals